NASDAQ:ACTU Actuate Therapeutics (ACTU) Stock Price, News & Analysis $8.44 +0.22 (+2.68%) Closing price 04:00 PM EasternExtended Trading$8.45 +0.01 (+0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Actuate Therapeutics Stock (NASDAQ:ACTU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Actuate Therapeutics alerts:Sign Up Key Stats Today's Range$8.02▼$8.5550-Day Range$5.66▼$8.6752-Week Range$5.47▼$11.99Volume41,064 shsAverage Volume55,980 shsMarket Capitalization$175.13 millionP/E RatioN/ADividend YieldN/APrice Target$20.33Consensus RatingBuy Company Overview Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas. Read More Receive ACTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACTU Stock News HeadlinesQ3 Earnings Forecast for ACTU Issued By B. RileyAugust 29 at 2:19 AM | americanbankingnews.comDelveInsight Business Research, LLP: GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsightAugust 28 at 6:24 PM | finanznachrichten.deMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 29 at 2:00 AM | Brownstone Research (Ad)GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsightAugust 28 at 6:24 PM | finance.yahoo.comActuate Therapeutics (NASDAQ:ACTU) Coverage Initiated by Analysts at B. RileyAugust 27 at 2:53 AM | americanbankingnews.comB. Riley Securities Initiates Coverage of Actuate Therapeutics (ACTU) with Buy RecommendationAugust 26 at 4:54 PM | msn.comActuate Therapeutics initiated with a Buy at B. RileyAugust 26 at 11:54 AM | msn.comActuate Therapeutics (NASDAQ:ACTU) Cut to "Sell" at Wall Street ZenAugust 23, 2025 | americanbankingnews.comSee More Headlines ACTU Stock Analysis - Frequently Asked Questions How have ACTU shares performed this year? Actuate Therapeutics' stock was trading at $7.96 at the beginning of the year. Since then, ACTU stock has increased by 6.0% and is now trading at $8.44. How were Actuate Therapeutics' earnings last quarter? Actuate Therapeutics, Inc. (NASDAQ:ACTU) issued its earnings results on Thursday, August, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.11. When did Actuate Therapeutics IPO? Actuate Therapeutics (ACTU) raised $27 million in an initial public offering on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager. Who are Actuate Therapeutics' major shareholders? Actuate Therapeutics' top institutional shareholders include BIOS Capital Management LP (48.68%), Voss Capital LP (1.40%), Geode Capital Management LLC (0.58%) and Gleason Group Inc. (0.10%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Equity Cof Lp Bios and Aaron GL Fletcher. View institutional ownership trends. How do I buy shares of Actuate Therapeutics? Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actuate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN). Company Calendar Last Earnings8/14/2025Today8/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACTU Previous SymbolNASDAQ:ACTU CIK1652935 WebN/A Phone(847) 986-4190FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Actuate Therapeutics$20.33 High Price Target$21.00 Low Price Target$20.00 Potential Upside/Downside+138.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.28 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-281.83% Debt Debt-to-Equity RatioN/A Current Ratio0.73 Quick Ratio0.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-65.49Miscellaneous Outstanding Shares20,745,000Free Float6,360,000Market Cap$176.62 million OptionableN/A BetaN/A Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ACTU) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.